Canadian society: cardiac care is under-represented in wait strategy:
This article was originally published in Clinica
Executive Summary
The Canadian Cardiovascular Society (CCS - Ottawa) has criticised Canada's wait time alliance (WTA) report (see Clinica No 1253, p 15) as failing to provide "the big picture of cardiac care". The WTA adopts a benchmark only for cardiac bypass surgery (CABG - which received the desirable "A" grade). However, there is a whole spectrum of services surrounding cardiac care, such as the wait time to see a cardiologist, to have relevant tests, or to obtain rehabilitation services, as well as other, more common, cardiac operations such as angioplasty, which is twice as common as CABG in Canada, says the CCS. By considering only CABG, "governments are not making a meaningful and positive impact on wait times for Canadians", said Dr Blair O'Neill, chair of the CCS' access to care working group. "What we'd like to see is the full spectrum of cardiac care benchmarks adopted by all provinces," said Dr Chris Simpson, co-chair of the working group.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.